In Vivo Biodistribution, PET Imaging, and Tumor Accumulation of Y-86- and In-111-Antimindin/RG-1, Engineered Antibody Fragments in LNCaP Tumor-Bearing Nude Mice

Cancer Research, Berlex Biosciences/Schering AG, Richmond, California, USA.
Journal of Nuclear Medicine (Impact Factor: 6.16). 03/2009; 50(3):435-43. DOI: 10.2967/jnumed.108.055608
Source: PubMed


To optimize in vivo tissue uptake kinetics and clearance of engineered monoclonal antibody (mAb) fragments for radiotherapeutic and radiodiagnostic applications, we compared the biodistribution and tumor localization of four (111)In- and (86)Y-labeled antibody formats, derived from a single antimindin/RG-1 mAb, in a prostate tumor model. The IgG, diabody, single-chain variable domain (scFv), and novel miniantibody formats, composed of the human IgE-C(H)4 and a modified IgG1 hinge linked to scFv domains, were compared.
Antibodies were first derivatized with the bifunctional chelator CHX-A''-diethylenetriamine pentaacetic acid and then bound to the radiometal to create radiolabeled immunoconjugates. Human LNCaP xenografts were grown in nude mice, and (111)In- or (86)Y-labeled antibodies were administered intravenously. Tissues were harvested at different times, and the level of antibody deposition was determined by measuring radioactivity. Whole-body small-animal PET of mice receiving (86)Y-labeled antibodies was performed at 6 time points and colocalized with simultaneous micro-CT imaging.
The biodistributions of (111)In and (86)Y antibodies were quite similar. The blood, tumor, kidney, and liver tissues contained varying levels of radioactivity. The antibody accumulation in the tumor correlated with molecular size. The IgG steadily increased with time to 24.1 percentage injected dose per gram (%ID/g) at 48 h. The miniantibody accumulated at a similar rate to reach a lower level (14.2 %ID/g) at 48 h but with a higher tumor-to-blood ratio than the IgG. Tumor accumulation of the diabody peaked at 3 h, reaching a much lower level (3.7 %ID/g). A combination of rapid clearance and lower relative affinity of the scFv precluded deposition in the tumor. Small-animal PET results correlated well with the biodistribution results, with similar tumor localization patterns.
The larger antibody formats (IgG and miniantibody) gave higher tumor uptake levels than did the smaller formats (diabody and scFv). These larger formats may be more suitable for radioimmunotherapy applications, evidenced by the preclinical efficacy previously shown by a report on the IgG format. The smaller formats were rapidly cleared from circulation, and the diabody, which accumulated in the tumor, may be more suitable for radiodiagnostic applications.

Download full-text


Available from: Tara Heitner, May 19, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper presents an efficient approach to short term power system resource scheduling based on the augmented Lagrangian relaxation method. The problem is divided into two stages, the commitment stage and the constrained economic dispatch stage. The proposed mathematical model incorporates optimal power flow (OPF) constraints in the unit commitment stage. By OPF constrains, the authors refer to the relevant active power constraints that are incorporated in the constrained economic dispatch stage (i.e. transmission capacity constraints, fuel and various regulated emission requirements). The inclusion of OPF constraints in the commitment stage will improve the feasibility of the constrained economic dispatch solution. Other unit commitment constraints such as spinning and operating reserve requirements, power balance as well as other relevant local constraints (i.e. unit ramping rates, upper and lower generation limits, minimum up and down times) are taken into account in the proposed model. As a larger number of constraints are dealt with, a more rigorous method is introduced for updating Lagrange multipliers to improve the solution convergence. A software package which addresses energy management systems requirements is developed and tested
    Power Industry Computer Application Conference, 1995. Conference Proceedings., 1995 IEEE; 06/1995

  • Yakushigaku zasshi. The Journal of Japanese history of pharmacy 02/1996; 31(1):1-6.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Here we present a bispecific antibody (bsAb) format in which a disulfide-stabilized scFv is fused to the C-terminus of the light chain of an IgG to create an IgG-scFv bifunctional antibody. When expressed in mammalian cells and purified by one-step protein A chromatography, the bsAb retains parental affinities of each binding domain, exhibits IgG-like stability and demonstrates in vivo IgG-like tumor targeting and blood clearance. The extension of the C-terminus of the light chain of an IgG with an scFv or even a smaller peptide does appear to disrupt disulfide bond formation between the light and heavy chains; however, this does not appear to affect binding, stability or in vivo properties of the IgG. Thus, we demonstrate here that the light chain of an IgG can be extended with an scFv without affecting IgG function and stability. This format serves as a standardized platform for the construction of functional bsAbs.
    Protein Engineering Design and Selection 12/2009; 23(4):221-8. DOI:10.1093/protein/gzp077 · 2.54 Impact Factor
Show more